Kewen He

1.4k total citations · 1 hit paper
34 papers, 838 citations indexed

About

Kewen He is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kewen He has authored 34 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 11 papers in Immunology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kewen He's work include Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Kewen He is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Kewen He collaborates with scholars based in China, United States and Türkiye. Kewen He's co-authors include James W. Welsh, Dawei Chen, Roshal R. Patel, Hampartsoum B. Barsoumian, Vivek Verma, María Angélica Cortez, Heike Peulen, Joachim G.J.V. Aerts, Quynh-Nhu Nguyen and Joe Y. Chang and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Kewen He

32 papers receiving 829 citations

Hit Papers

Pembrolizumab with or without radiotherapy for metastatic... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
    2020 353 citations Willemijn S.M.E. Theelen, Dawei Chen et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kewen He China 14 516 296 224 175 126 34 838
Jonathan E. Schoenhals United States 14 457 0.9× 253 0.9× 322 1.4× 124 0.7× 89 0.7× 22 744
Qingsong Pang China 17 416 0.8× 449 1.5× 89 0.4× 188 1.1× 87 0.7× 87 867
Kobe Reynders Netherlands 7 388 0.8× 217 0.7× 164 0.7× 60 0.3× 47 0.4× 12 550
Jesús Rodríguez-Pascual Spain 10 404 0.8× 125 0.4× 51 0.2× 111 0.6× 143 1.1× 28 550
Kyung Ran Park South Korea 13 283 0.5× 144 0.5× 84 0.4× 50 0.3× 92 0.7× 24 595
Yoshiki Shigematsu Japan 18 407 0.8× 413 1.4× 308 1.4× 187 1.1× 78 0.6× 44 876
Tomohiro Fujii Japan 19 261 0.5× 310 1.0× 43 0.2× 216 1.2× 65 0.5× 47 887
Ari J. Rosenberg United States 14 336 0.7× 160 0.5× 74 0.3× 141 0.8× 83 0.7× 69 636

Countries citing papers authored by Kewen He

Since Specialization
Citations

This map shows the geographic impact of Kewen He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kewen He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kewen He more than expected).

Fields of papers citing papers by Kewen He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kewen He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kewen He. The network helps show where Kewen He may publish in the future.

Co-authorship network of co-authors of Kewen He

This figure shows the co-authorship network connecting the top 25 collaborators of Kewen He. A scholar is included among the top collaborators of Kewen He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kewen He. Kewen He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Yong, Kewen He, Yang Zhang, et al.. (2024). Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy. Journal of Pharmaceutical Analysis. 15(3). 101082–101082. 1 indexed citations
2.
He, Kewen, Nahum Puebla‐Osorio, Hampartsoum B. Barsoumian, et al.. (2024). Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. Journal of Experimental & Clinical Cancer Research. 43(1). 251–251. 3 indexed citations
3.
He, Kewen, David S. Hong, Chad Tang, et al.. (2023). Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiotherapy and Oncology. 183. 109618–109618. 3 indexed citations
4.
Barsoumian, Hampartsoum B., Kewen He, Duygu Sezen, et al.. (2023). NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunology Immunotherapy. 72(9). 3003–3012. 15 indexed citations
5.
Hu, Yun, Sébastien Paris, Hampartsoum B. Barsoumian, et al.. (2022). Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. Journal of Nanobiotechnology. 20(1). 417–417. 24 indexed citations
6.
He, Kewen, Jie Yin, Dezhi Mu, et al.. (2021). Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Toxicity and Efficacy in Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 111(3). e437–e437. 2 indexed citations
7.
He, Wei, et al.. (2021). Experimental noise and vibration characteristics of elevated urban rail transit considering the effect of track structures and noise barriers. Environmental Science and Pollution Research. 28(33). 45903–45919. 12 indexed citations
8.
He, Kewen, Hampartsoum B. Barsoumian, Vivek Verma, et al.. (2021). Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Frontiers in Immunology. 12. 812210–812210. 20 indexed citations
9.
He, Kewen, Hampartsoum B. Barsoumian, Duygu Sezen, et al.. (2021). Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Frontiers in Oncology. 11. 737425–737425. 14 indexed citations
10.
Sezen, Duygu, Vivek Verma, Kewen He, et al.. (2021). Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Seminars in Radiation Oncology. 31(3). 217–226. 4 indexed citations
11.
Hu, Yun, Sébastien Paris, Hampartsoum B. Barsoumian, et al.. (2021). A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. Journal of Nanobiotechnology. 19(1). 416–416. 25 indexed citations
12.
He, Kewen, Roshal R. Patel, Joe Y. Chang, et al.. (2021). Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration. International Journal of Radiation Oncology*Biology*Physics. 111(3). S118–S118. 3 indexed citations
13.
Theelen, Willemijn S.M.E., Dawei Chen, Vivek Verma, et al.. (2020). Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Respiratory Medicine. 9(5). 467–475. 353 indexed citations breakdown →
14.
Younes, Ahmed, Hampartsoum B. Barsoumian, Duygu Sezen, et al.. (2020). Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Translational Oncology. 14(2). 100983–100983. 20 indexed citations
15.
Klein, Katherine, Kewen He, Ahmed Younes, et al.. (2020). Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Frontiers in Immunology. 11. 573326–573326. 81 indexed citations
16.
He, Kewen, Shaotong Zhang, Liang Shao, et al.. (2019). Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters. 472. 108–118. 8 indexed citations
17.
He, Kewen, Xinzhao Wang, Xiyun Guan, et al.. (2017). Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer. Anticancer Research. 37(10). 5647–5653. 4 indexed citations
18.
Liu, Zhaoyun, Kewen He, Qinghua Ma, et al.. (2017). Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer. PLoS ONE. 12(5). e0177694–e0177694. 46 indexed citations
19.
He, Kewen, et al.. (2017). Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. Medicine. 96(44). e8490–e8490. 13 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan E. Schoenhals Breakdown of academic impact, for papers by Qingsong Pang Breakdown of academic impact, for papers by Kobe Reynders Breakdown of academic impact, for papers by Jesús Rodríguez-Pascual Breakdown of academic impact, for papers by Kyung Ran Park Breakdown of academic impact, for papers by Yoshiki Shigematsu Breakdown of academic impact, for papers by Tomohiro Fujii Breakdown of academic impact, for papers by Ari J. Rosenberg
Rankless by CCL
2026